Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Provides-Update-on-FY-2022-Financial-Guidance-and-Announces-FY-2023-Financial-Guidance/default.aspx
Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Present-at-the-41st-Annual-J.P.-Morgan-Healthcare-Conference/default.aspx
AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age
https://news.abbvie.com/news/press-releases/abbvie-submits-supplemental-new-drug-application-to-us-fda-to-support-new-indication-linzess-linaclotide-for-functional-constipation-in-children-and-adolescents-6-to-17-years-age.htm
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Participate-in-the-Piper-Sandler-34th-Annual-Healthcare-Conference/default.aspx
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Participate-in-the-Piper-Sandler-34th-Annual-Healthcare-Conference/default.aspx
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Strong-Third-Quarter-2022-Results-Maintains-Full-Year-2022-Financial-Guidance/default.aspx
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Strong-Third-Quarter-2022-Results-Maintains-Full-Year-2022-Financial-Guidance/default.aspx
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2022-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2022-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Positive-Topline-Data-from-Phase-III-Trial-of-LINZESS-linaclotide-in-Pediatric-Patients-Aged-6-17-with-Functional-Constipation/default.aspx
